Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068549 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00068549 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 13 participants.
The verdict
NCT00068549, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining cisplatin with gemcitabine may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells.
Interventions
- DRUG Cisplatin
- RADIATION Radiation Therapy
- DRUG Gemcitabine Hydrochloride
- RADIATION Internal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2003-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068549
The ClinicalTrials.gov registry entry for NCT00068549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00068549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068549 about?
NCT00068549 is a clinical study titled "Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer". This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemot...
What is the current status of trial NCT00068549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2003-10.
What interventions are being tested in trial NCT00068549?
The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (RADIATION), Gemcitabine Hydrochloride (DRUG), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00068549?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.